An overview of the advancements in therapeutic strategies developed for disease-modifying treatment and biomarkers in PD, with a focus on the most common genetic targets SNCA, LRRK2, and GBA1, and their applications in idiopathic PD. Here, GBA1 is linked to Parkinson disease.